Calcitriol - Galderma

Drug Profile

Calcitriol - Galderma

Alternative Names: Silkis; Vectical

Latest Information Update: 29 Aug 2014

Price : $50

At a glance

  • Originator Savient Pharmaceuticals
  • Developer Galderma
  • Class Antipsoriatics; Chemoprotectants; Dihydroxycholecalciferols; Osteoporosis therapies; Small molecules; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Plaque psoriasis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Jul 2014 Galderma initiates enrolment in a phase IV trial for Plaque psoriasis (In children) in USA (NCT02186665)
  • 28 Mar 2014 Clinical trials in Plaque psoriasis (In children, In adolescents) in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top